fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Doxazosin mesylate

9 general benefit · 3 not a benefit

Apo-Doxazosin · DIN 02240588 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Doxazosin · DIN 02240588 Manufacturer: Apotex Inc.; listing date 2000-01-17 Daily cost (source): $0.1719 Health Canada: Marketed since 1999-07-22 · brand APO-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 1 MG/TAB · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Doxazosin: Formulary list price $0.17 per unit (the source does not state the unit; exact figure $0.1719). What the ministry pays, not the patient.

Ministry pays: $0.1719 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240588)

Source record
DIN 02240588: Apo-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800168; group id 321; item number 0712; lccId None; manufacturer id APX Source form: Tab; strength: 1mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1719; ministry $0.1719 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240588 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64159
Interchangeable products
Cardura-1 · DIN 01958100 · not recorded Jamp-Doxazosin · DIN 02489937 · $0.1719 Teva-Doxazosin · DIN 02242728 · $0.1719
Shortage status: resolved shortage (ended October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240588
Shortage record checked October 6, 2026

Jamp-Doxazosin · DIN 02489937 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Doxazosin · DIN 02489937 Manufacturer: Jamp Pharma Corporation; listing date 2020-06-30 Daily cost (source): $0.1719 Health Canada: Marketed since 2020-05-06 · brand JAMP-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 1 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Doxazosin: Formulary list price $0.17 per unit (the source does not state the unit; exact figure $0.1719). What the ministry pays, not the patient.

Ministry pays: $0.1719 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02489937)

Source record
DIN 02489937: Jamp-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800168; group id 321; item number 0712; lccId None; manufacturer id JPC Source form: Tab; strength: 1mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1719; ministry $0.1719 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02489937 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98001
Interchangeable products
Apo-Doxazosin · DIN 02240588 · $0.1719 Cardura-1 · DIN 01958100 · not recorded Teva-Doxazosin · DIN 02242728 · $0.1719
Shortage status: active shortage (reported September 15, 2026, estimated to end March 12, 2027, last updated September 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489937
Shortage record checked October 6, 2026

Teva-Doxazosin · DIN 02242728 · 1 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Doxazosin · DIN 02242728 Manufacturer: Teva Canada Limited; listing date 2001-03-07 Daily cost (source): $0.1719 Health Canada: Marketed since 2014-02-07 · brand TEVA-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 1 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Doxazosin: Formulary list price $0.17 per unit (the source does not state the unit; exact figure $0.1719). What the ministry pays, not the patient.

Ministry pays: $0.1719 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242728)

Source record
DIN 02242728: Teva-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800168; group id 321; item number 0712; lccId None; manufacturer id TEV Source form: Tab; strength: 1mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1719; ministry $0.1719 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242728 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66535
Interchangeable products
Apo-Doxazosin · DIN 02240588 · $0.1719 Cardura-1 · DIN 01958100 · not recorded Jamp-Doxazosin · DIN 02489937 · $0.1719
Shortage status: resolved shortage (ended July 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242728
Shortage record checked October 6, 2026

Apo-Doxazosin · DIN 02240589 · 2 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Doxazosin · DIN 02240589 Manufacturer: Apotex Inc.; listing date 2000-01-17 Daily cost (source): $0.2062 Health Canada: Marketed since 1999-07-22 · brand APO-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 2 MG/TAB · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Doxazosin: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2062). What the ministry pays, not the patient.

Ministry pays: $0.2062 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240589)

Source record
DIN 02240589: Apo-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800169; group id 321; item number 0713; lccId None; manufacturer id APX Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2062; ministry $0.2062 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240589 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64160
Interchangeable products
Cardura-2 · DIN 01958097 · not recorded Jamp-Doxazosin · DIN 02489945 · $0.2062 Teva-Doxazosin · DIN 02242729 · $0.2062
Shortage status: resolved shortage (ended June 26, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240589
Shortage record checked October 6, 2026

Jamp-Doxazosin · DIN 02489945 · 2 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Doxazosin · DIN 02489945 Manufacturer: Jamp Pharma Corporation; listing date 2020-06-30 Daily cost (source): $0.2062 Health Canada: Marketed since 2020-05-06 · brand JAMP-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 2 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Doxazosin: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2062). What the ministry pays, not the patient.

Ministry pays: $0.2062 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02489945)

Source record
DIN 02489945: Jamp-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800169; group id 321; item number 0713; lccId None; manufacturer id JPC Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2062; ministry $0.2062 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02489945 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98002
Interchangeable products
Apo-Doxazosin · DIN 02240589 · $0.2062 Cardura-2 · DIN 01958097 · not recorded Teva-Doxazosin · DIN 02242729 · $0.2062
Shortage status: resolved shortage (ended July 25, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489945
Shortage record checked October 6, 2026

Teva-Doxazosin · DIN 02242729 · 2 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Doxazosin · DIN 02242729 Manufacturer: Teva Canada Limited; listing date 2001-03-07 Daily cost (source): $0.2062 Health Canada: Marketed since 2014-02-07 · brand TEVA-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 2 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Doxazosin: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2062). What the ministry pays, not the patient.

Ministry pays: $0.2062 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242729)

Source record
DIN 02242729: Teva-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800169; group id 321; item number 0713; lccId None; manufacturer id TEV Source form: Tab; strength: 2mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2062; ministry $0.2062 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242729 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66536
Interchangeable products
Apo-Doxazosin · DIN 02240589 · $0.2062 Cardura-2 · DIN 01958097 · not recorded Jamp-Doxazosin · DIN 02489945 · $0.2062
Shortage status: resolved shortage (ended January 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242729
Shortage record checked October 6, 2026

Apo-Doxazosin · DIN 02240590 · 4 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Doxazosin · DIN 02240590 Manufacturer: Apotex Inc.; listing date 2000-01-17 Daily cost (source): $0.2681 Health Canada: Marketed since 1999-07-22 · brand APO-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 4 MG/TAB · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Doxazosin: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2681). What the ministry pays, not the patient.

Ministry pays: $0.2681 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240590)

Source record
DIN 02240590: Apo-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800170; group id 321; item number 0714; lccId None; manufacturer id APX Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2681; ministry $0.2681 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240590 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64161
Interchangeable products
Cardura-4 · DIN 01958119 · not recorded Jamp-Doxazosin · DIN 02489953 · $0.2681 Teva-Doxazosin · DIN 02242730 · $0.2681
Shortage status: resolved shortage (ended September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240590
Shortage record checked October 6, 2026

Jamp-Doxazosin · DIN 02489953 · 4 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Doxazosin · DIN 02489953 Manufacturer: Jamp Pharma Corporation; listing date 2020-06-30 Daily cost (source): $0.2681 Health Canada: Marketed since 2020-05-06 · brand JAMP-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 4 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp-Doxazosin: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2681). What the ministry pays, not the patient.

Ministry pays: $0.2681 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02489953)

Source record
DIN 02489953: Jamp-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800170; group id 321; item number 0714; lccId None; manufacturer id JPC Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2681; ministry $0.2681 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02489953 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98003
Interchangeable products
Apo-Doxazosin · DIN 02240590 · $0.2681 Cardura-4 · DIN 01958119 · not recorded Teva-Doxazosin · DIN 02242730 · $0.2681
Shortage status: resolved shortage (ended July 25, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489953
Shortage record checked October 6, 2026

Teva-Doxazosin · DIN 02242730 · 4 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Doxazosin · DIN 02242730 Manufacturer: Teva Canada Limited; listing date 2001-03-07 Daily cost (source): $0.2681 Health Canada: Marketed since 2014-02-07 · brand TEVA-DOXAZOSIN · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 4 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Doxazosin: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2681). What the ministry pays, not the patient.

Ministry pays: $0.2681 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242730)

Source record
DIN 02242730: Teva-Doxazosin Raw flags: chronicUseMed=Y, sec3=Y Item: 240800170; group id 321; item number 0714; lccId None; manufacturer id TEV Source form: Tab; strength: 4mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2681; ministry $0.2681 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242730 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66537
Interchangeable products
Apo-Doxazosin · DIN 02240590 · $0.2681 Cardura-4 · DIN 01958119 · not recorded Jamp-Doxazosin · DIN 02489953 · $0.2681
Shortage status: resolved shortage (ended April 17, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242730
Shortage record checked October 6, 2026

Cardura-1 · DIN 01958100 · 1 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.Discontinued September 30, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Cardura-1 · DIN 01958100 Manufacturer: AstraZeneca; listing date 1996-10-01 Daily cost (source): $0.1719 Health Canada: Cancelled post market since 2018-09-30 · brand CARDURA-1 TAB 1MG · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 1 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cardura-1: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01958100)

Source record
DIN 01958100: Cardura-1 Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800168; group id 321; item number 0712; lccId None; manufacturer id AZC Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01958100 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12455
Interchangeable products
Apo-Doxazosin · DIN 02240588 · $0.1719 Jamp-Doxazosin · DIN 02489937 · $0.1719 Teva-Doxazosin · DIN 02242728 · $0.1719
Shortage status: discontinued (September 30, 2018, reported by PFIZER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01958100
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 30, 2018 — choose a marketed DIN from the same-category list.

Cardura-2 · DIN 01958097 · 2 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.Discontinued September 30, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Cardura-2 · DIN 01958097 Manufacturer: AstraZeneca; listing date 1996-10-01 Daily cost (source): $0.2062 Health Canada: Cancelled post market since 2018-09-30 · brand CARDURA-2 TAB 2MG · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 2 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cardura-2: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01958097)

Source record
DIN 01958097: Cardura-2 Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800169; group id 321; item number 0713; lccId None; manufacturer id AZC Source form: Tab; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01958097 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12456
Interchangeable products
Apo-Doxazosin · DIN 02240589 · $0.2062 Jamp-Doxazosin · DIN 02489945 · $0.2062 Teva-Doxazosin · DIN 02242729 · $0.2062
Shortage status: discontinued (September 30, 2018, reported by PFIZER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01958097
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 30, 2018 — choose a marketed DIN from the same-category list.

Cardura-4 · DIN 01958119 · 4 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.Discontinued September 30, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-09-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Cardura-4 · DIN 01958119 Manufacturer: AstraZeneca; listing date 1996-10-01 Daily cost (source): $0.2681 Health Canada: Cancelled post market since 2018-09-30 · brand CARDURA-4 TAB 4MG · ATC C02CA04 DOXAZOSIN · form Tablet · route Oral · ingredients DOXAZOSIN (DOXAZOSIN MESYLATE) 4 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cardura-4: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01958119)

Source record
DIN 01958119: Cardura-4 Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800170; group id 321; item number 0714; lccId None; manufacturer id AZC Source form: Tab; strength: 4mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01958119 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12457
Interchangeable products
Apo-Doxazosin · DIN 02240590 · $0.2681 Jamp-Doxazosin · DIN 02489953 · $0.2681 Teva-Doxazosin · DIN 02242730 · $0.2681
Shortage status: discontinued (September 30, 2018, reported by PFIZER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01958119
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 30, 2018 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (C02CA): coverage varies; not interchangeable

  • Prazosin (Prazosin Hydrochloride Capsules, USP): general benefit, listing status unconfirmed
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

PRAZOSIN HCL

· 12 products · Temporary benefit (3), General benefit (9) · strengths: 1mg, 2mg, 5mg · Cap, Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: symptoms of benign prostatic hyperplasia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. TERAZOSIN HCL · Listed, not a benefit (4), General benefit (8) - the treatment of symptoms of benign prostatic hyperplasia (BPH). PM: https://pdf.hres.ca/dpd_pm/00063013.PDF; date September 16, 2021; DIN 02234502; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Hypertension APO-DOXAZOSIN (doxazosin mesylate) is indicated in the treatment of mild to moderate essential hypertension. It is employed in a general treatment program in association with a thiazide diuretic and/or other antihypertensive agents, as needed, for proper patient response. APO-DOXAZOSIN may be tried as a sole therapy in those patients for whom treatment with other agents caused adverse effects or is inappropriate. Benign Prostatic Hyperplasia (BPH) APO-DOXAZOSIN is also indicated for the treatment of symptoms of benign prostatic hyperplasia (BPH). The onset of effect is rapid, with improvement in peak flow and symptoms observed within 1 to 2 weeks. The effect on these variables was maintained over the entire study duration (≤4 years). APO-DOXAZOSIN may be used in BPH patients who are either hypertensive or normotensive. While the reduction in blood pressure in normotensive patients with BPH is clinically insignificant, patients with hypertension and BPH have both conditions effectively treated with doxazosin monotherapy (see DOSAGE and ADMINISTRATION for dosage regiments). A number of clinical condit… https://pdf.hres.ca/dpd_pm/00048001.PDF PM date: October 29, 2018 Source product: APO-DOXAZOSIN; DIN 02240588; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Jamp-Doxazosin · DIN 02489937 Shortage status: active shortage (reported 2026-09-15, estimated to end 2027-03-12, last updated 2026-09-23); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489937

Check this DIN again

Cardura-1 · DIN 01958100 Shortage status: discontinued (2018-09-30, reported by PFIZER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01958100

Check this DIN again

Cardura-2 · DIN 01958097 Shortage status: discontinued (2018-09-30, reported by PFIZER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01958097

Check this DIN again

Cardura-4 · DIN 01958119 Shortage status: discontinued (2018-09-30, reported by PFIZER CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01958119

Check this DIN again

Other review policies

For Cardura-1, Cardura-2, Cardura-4: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026